Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma and Tularik Announce Library Synthesis Agreement
Boulder, CO and South San Francisco, CA – May 10, 2000 – Array BioPharma and Tularik Inc. (NASDAQ: TLRK) today announced an agreement for the design and synthesis of a small molecule focused library targeting orphan nuclear receptors. Array BioPharma has created innovations in high-speed synthesis and parallel purification to facilitate the rapid production of high quality, small molecule libraries. Array will couple its expertise in the design and synthesis of small molecule libraries with Tularik’s knowledge of nuclear receptors to produce a library focused on creating valuable information and potential leads for this important class of therapeutic targets. Based on analyses of screening data against multiple nuclear receptors, the library may have widespread screening utility. Following a period of exclusivity with Tularik, Array has the right to offer compounds in the library to third parties. “We are excited about initiating our second agreement with Tularik,” said Kevin Koch, Ph.D., President and Chief Science Officer at Array. “This agreement, which exploits our expertise in chemical genomics, is focused on creating powerful tools to both study orphan nuclear receptors and develop novel therapeutic leads.” “We are pleased to expand our collaboration with Array BioPharma and believe this collaboration accelerates Tularik’s ability to broaden our knowledge of the function and activity of orphan nuclear receptors,” said Juan C. Jaen, Ph.D., Director of Chemistry, "Tularik continues to be impressed with Array’s ability to create valuable synthetic libraries that complement our internal work in the discovery of novel therapeutics.” Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs based on gene regulation. Tularik programs address cancer, CMV, diabetes, obesity, inflammation, allergy/asthma, hypercholesterolemia and bacterial diseases, and a class of targets known as orphan nuclear receptors. Tularik has established strategic partnerships with Japan Tobacco Inc., Roche Bioscience and Knoll AG. For additional information, visit Tularik’s Internet web site at

Array BioPharma Inc., based in Boulder, Colorado, is a privately held discovery research organization (DRO™) comprised of leading chemists. The company provides enabling technologies and world class research services in all aspects of chemistry, high-throughput screening, structural biology and information management. Array BioPharma is at the forefront of translating genomic discoveries into safe and effective therapeutics. For additional information, visit Array’s web site at

Statements in this press release that are not strictly historical are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. There can be no assurance that Tularik will obtain necessary regulatory approvals for its drug candidates or be able to develop a commercially viable pharmaceutical product. These and other risks are more fully discussed in Tularik’s SEC reports, including the report on Form 10-K for the year ended December 31, 1999.

Contact Info:

David Snitman